Literature DB >> 33922278

The Effect of Genetic Polymorphism in Response to Body Weight Reduction in Japanese Patients with Nonalcoholic Fatty Liver Disease.

Yuya Seko1, Kanji Yamaguchi1, Nozomi Tochiki1, Kota Yano1, Aya Takahashi1, Shinya Okishio1, Seita Kataoka1, Keiichiroh Okuda1, Atsushi Umemura1, Michihisa Moriguchi1, Yoshito Itoh1.   

Abstract

BACKGROUND: weight loss as a result of lifestyle intervention is effective when treating non-alcoholic fatty liver disease (NAFLD). We estimated the effects of PNPLA3 rs738409 and HSD17B13 rs6834314 variants in response to diet therapy in Japanese patients with NAFLD.
METHODS: we analyzed the correlation between the change in liver stiffness and change in body weight in 140 patients administered diet therapy for 1-year, according to PNPLA3 and HSD17B13 genotypes.
RESULTS: the bodyweight (BW) reduction rate was greater in patients with the PNPLA3 genotype CC than CG and GG (p = 0.035). Change in liver stiffness measurement (LSM) was significantly associated with a change in BW in PNPLA3 CG/GG (r = 0.279/0.381), but not in PNPLA3 CC (p = 0.187). Change in LSM was correlated with change in BW only in patients with HSD17B13 AG/GG (r = 0.425), but not the AA genotype (p = 0.069). A multivariate analysis identified that a change in LSM was correlated with a change in BW in carriers of HSD17B13 AG/GG (B = 3.043, p = 0.032), but not HSD17B13 AA. The change in LSM of patients with a BW reduction of more than 7% (0.50) was significantly greater than that of patients with a BW reduction of less than 7% (0.83) (p = 0.038).
CONCLUSIONS: in Japanese patients with NAFLD, HSD17B13 rs6834314 polymorphism is associated with the change in LSM by lifestyle intervention. The approach, including genetic assessments, may contribute to the establishment of appropriate therapeutic strategies to treat NAFLD.

Entities:  

Keywords:  HSD17B13; NAFLD; PNPLA3; SNP; diet therapy

Year:  2021        PMID: 33922278     DOI: 10.3390/genes12050628

Source DB:  PubMed          Journal:  Genes (Basel)        ISSN: 2073-4425            Impact factor:   4.096


  37 in total

Review 1.  The effect of PNPLA3 on fibrosis progression and development of hepatocellular carcinoma: a meta-analysis.

Authors:  Amit G Singal; Hema Manjunath; Adam C Yopp; Muhammad S Beg; Jorge A Marrero; Purva Gopal; Akbar K Waljee
Journal:  Am J Gastroenterol       Date:  2014-01-21       Impact factor: 10.864

2.  17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.

Authors:  Yanling Ma; Olga V Belyaeva; Philip M Brown; Koji Fujita; Katherine Valles; Suman Karki; Ynto S de Boer; Christopher Koh; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Vincent Chen; Elizabeth K Speliotes; Cara Nestlerode; Emmanuel Thomas; David E Kleiner; Joseph M Zmuda; Arun J Sanyal; Natalia Y Kedishvili; T Jake Liang; Yaron Rotman
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

3.  Influence of the rs738409 polymorphism in patatin-like phospholipase 3 on the treatment efficacy of non-alcoholic fatty liver disease with type 2 diabetes mellitus.

Authors:  Hiromi Kan; Hideyuki Hyogo; Hidenori Ochi; Kikuko Hotta; Takayuki Fukuhara; Tomoki Kobayashi; Noriaki Naeshiro; Yohji Honda; Tomokazu Kawaoka; Masataka Tsuge; Akira Hiramatsu; Michio Imamura; Yoshiiku Kawakami; Hiroshi Aikata; Kazuaki Chayama
Journal:  Hepatol Res       Date:  2015-07-29       Impact factor: 4.288

4.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

Authors:  C A Matteoni; Z M Younossi; T Gramlich; N Boparai; Y C Liu; A J McCullough
Journal:  Gastroenterology       Date:  1999-06       Impact factor: 22.682

5.  Genome-wide association study identifies variants associated with histologic features of nonalcoholic Fatty liver disease.

Authors:  Naga Chalasani; Xiuqing Guo; Rohit Loomba; Mark O Goodarzi; Talin Haritunians; Soonil Kwon; Jinrui Cui; Kent D Taylor; Laura Wilson; Oscar W Cummings; Yii-Der Ida Chen; Jerome I Rotter
Journal:  Gastroenterology       Date:  2010-08-11       Impact factor: 22.682

6.  Design and validation of a histological scoring system for nonalcoholic fatty liver disease.

Authors:  David E Kleiner; Elizabeth M Brunt; Mark Van Natta; Cynthia Behling; Melissa J Contos; Oscar W Cummings; Linda D Ferrell; Yao-Chang Liu; Michael S Torbenson; Aynur Unalp-Arida; Matthew Yeh; Arthur J McCullough; Arun J Sanyal
Journal:  Hepatology       Date:  2005-06       Impact factor: 17.425

7.  Genetic variation in PNPLA3 (adiponutrin) confers sensitivity to weight loss-induced decrease in liver fat in humans.

Authors:  Ksenia Sevastianova; Anna Kotronen; Amalia Gastaldelli; Julia Perttilä; Antti Hakkarainen; Jesper Lundbom; Laura Suojanen; Marju Orho-Melander; Nina Lundbom; Eleuterio Ferrannini; Aila Rissanen; Vesa M Olkkonen; Hannele Yki-Järvinen
Journal:  Am J Clin Nutr       Date:  2011-04-27       Impact factor: 7.045

8.  PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.

Authors:  Marcin Krawczyk; Raúl Jiménez-Agüero; José M Alustiza; José I Emparanza; María J Perugorria; Luis Bujanda; Frank Lammert; Jesús M Banales
Journal:  Surg Obes Relat Dis       Date:  2016-07-01       Impact factor: 4.734

9.  Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors.

Authors:  Anna Kotronen; Markku Peltonen; Antti Hakkarainen; Ksenia Sevastianova; Robert Bergholm; Lina M Johansson; Nina Lundbom; Aila Rissanen; Martin Ridderstråle; Leif Groop; Marju Orho-Melander; Hannele Yki-Järvinen
Journal:  Gastroenterology       Date:  2009-06-12       Impact factor: 22.682

10.  Paradoxical lower serum triglyceride levels and higher type 2 diabetes mellitus susceptibility in obese individuals with the PNPLA3 148M variant.

Authors:  Colin N A Palmer; Cristina Maglio; Carlo Pirazzi; Maria Antonella Burza; Martin Adiels; Lindsay Burch; Louise A Donnelly; Helen Colhoun; Alexander S Doney; John F Dillon; Ewan R Pearson; Mark McCarthy; Andrew T Hattersley; Tim Frayling; Andrew D Morris; Markku Peltonen; Per-Arne Svensson; Peter Jacobson; Jan Borén; Lars Sjöström; Lena M S Carlsson; Stefano Romeo
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

View more
  1 in total

Review 1.  Impact of Genetic Polymorphism on Response to Therapy in Non-Alcoholic Fatty Liver Disease.

Authors:  José Ignacio Martínez-Montoro; Isabel Cornejo-Pareja; Ana María Gómez-Pérez; Francisco J Tinahones
Journal:  Nutrients       Date:  2021-11-15       Impact factor: 5.717

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.